Skip Navigation Links

Bookmark and Share
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

on 10/25/2021
TROPION-Lung08 phase 3 trial to evaluate the Daiichi Sankyo and AstraZeneca TROP2 directed ADC with Merck & Co., Inc., Kenilworth, NJ., USA’s anti-PD-1 therapy as combination regimen for first-line metastatic NSCLC TOKYO & MUNICH & BASKING RIDGE...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.